Flecainide

Evidence Level: L3

Predicted Indications: 9

Flecainide

Pharmacist Assessment Report

Flecainide: Stroke disorder

One-Sentence Summary

Flecainide is a class IC sodium channel blocker, originally used for rhythm control in atrial fibrillation. The TxGNN model predicts it may be useful for stroke disorder, but the link is indirect (through atrial arrhythmia prevention), with 1 Phase 3 clinical trial and about 20 publications currently related to this direction. No study shows a direct stroke benefit.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	Stroke disorder
TxGNN Prediction Score	0.9991
Evidence Level	L3
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, flecainide is a class IC sodium channel blocker (antiarrhythmic), its use in rhythm control for atrial fibrillation is established, and mechanistically it may be applicable to stroke only indirectly.

Atrial fibrillation is a major cause of cardioembolic stroke. If flecainide maintains sinus rhythm and prevents atrial arrhythmia, it could in theory reduce the risk of some cardioembolic events. However, this is a surrogate pathway. The available trial measures arrhythmia, not stroke recurrence, and the literature is mostly atrial fibrillation management reviews and observational studies.

Applicability is also limited because class IC agents are generally avoided in structural heart disease and after myocardial infarction, conditions common in stroke populations.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT05213104	Phase 3	Active, not recruiting (est. completion Sept 2026)	186	Flecainide to lower the risk of atrial arrhythmia or tachycardia after patent foramen ovale (PFO) closure, a procedure for secondary stroke prevention. The primary endpoint is arrhythmia, not stroke, so this is indirect evidence.

No ANZCTR trials were identified in the data compiled for this report.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
25820938	2015	Meta-analysis	Cochrane Database Syst Rev	Antiarrhythmics for maintaining sinus rhythm after cardioversion of AF (identified under the related cerebrovascular disorder prediction)
38702961	2024	Cohort	Europace	Safety and efficacy of long-term sodium channel blocker (flecainide, propafenone) therapy for early rhythm control in EAST-AFNET 4
41954064	2026	Cohort	J Am Heart Assoc	Long-term outcomes with class 1C antiarrhythmics in AF; benefit over rate control is still unclear
41152878	2025	Cohort	BMC Med	Concomitant DOACs and interacting antiarrhythmics and risk of stroke and bleeding in non-valvular AF
38551548	2024	Review	JACC Clin Electrophysiol	Class 1C antiarrhythmics for PVC suppression in nonischemic cardiomyopathy with ICDs
30067936	2018	Guideline	Med J Aust	Australian clinical guidelines for the diagnosis and management of AF
25430048	2014	Review	BMJ Clin Evid	Acute-onset AF; AF increases the risk of stroke and heart failure
19265095	2009	Review	Chest	Acute management of AF: rate versus rhythm control and thromboembolism
8729366	1995	Clinical study	Arch Mal Coeur Vaiss	Atrial electrophysiological study with IV flecainide in 38 patients with unexplained ischaemic cerebrovascular events
27884575	2017	Case report	J Emerg Med	Brugada pattern unmasked by flecainide overdose (safety signal)

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 1088G	Flecainide Sandoz	Tablet containing flecainide acetate 50 mg (oral)	Not available in the data compiled for this report

Safety Considerations

Contraindications suggested by the knowledge graph (not label text; must be verified against the Product Information): myocardial infarction, coronary thrombosis, atrioventricular block, sick sinus syndrome (including familial forms), kidney disease, liver disease, gallbladder disease, potassium deficiency, hemoglobinopathy, pyoureter.
Drug Interactions: 100 interactions were identified. Major interactions include dolasetron and eliglustat. Moderate interactions include famotidine, cimetidine, loperamide, bupropion, lorcaserin, clarithromycin, levofloxacin, palonosetron, trospium, and several laxatives and bowel preparations (bisacodyl, picosulfuric acid, polyethylene glycol with electrolytes, sodium sulfate, lactitol, lactulose). Minor interactions include ascorbic acid, potassium citrate and metronidazole.
Literature signals: proarrhythmic risk in patients with structural heart disease or ischaemia, Brugada pattern unmasking, and pharmacokinetic interactions between antiarrhythmics and DOACs, which is relevant in a stroke-prevention population.

Please also refer to the TGA-approved Product Information (PI) for full warnings and precautions.

Conclusion and Next Steps

Decision: Hold

Rationale: The evidence is indirect: the only Phase 3 trial targets post-PFO-closure arrhythmia rather than stroke, and the literature does not show a direct stroke benefit. Many stroke patients also have conditions (structural heart disease, prior myocardial infarction) in which flecainide is contraindicated, and safety screening cannot proceed without the label warnings.

To proceed, the following is needed:

Results of NCT05213104 (estimated completion September 2026), particularly any stroke or thromboembolic outcomes
Extraction of the warnings and contraindications from the TGA Product Information, and the approved indication text for the ARTG entry
Mechanism of action data
Analysis of stroke endpoints in existing class IC and EAST-AFNET 4 data
A defined target population (for example, AF patients without structural heart disease) and an assessment of DOAC co-prescribing interactions
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.